Generali Investments Management Co LLC Has $1.08 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK

Posted by George Bondi on Aug 11th, 2026

Generali Investments Management Co LLC boosted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 379.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,149 shares of the company’s stock after purchasing an additional 26,237 shares during the quarter. Generali Investments Management Co LLC owned about 0.05% of Stoke Therapeutics worth $1,085,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 1.2% during the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after buying an additional 354 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after acquiring an additional 359 shares during the last quarter. Strs Ohio grew its stake in shares of Stoke Therapeutics by 9.4% in the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after acquiring an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the period. Finally, First Trust Advisors LP increased its position in Stoke Therapeutics by 0.5% during the first quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock worth $5,322,000 after acquiring an additional 780 shares during the period.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 7,176 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the sale, the insider directly owned 20,422 shares in the company, valued at $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares in the company, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,428 shares of company stock valued at $306,919 in the last 90 days. 9.60% of the stock is owned by corporate insiders.

Stoke Therapeutics Stock Down 1.5%

NASDAQ:STOK opened at $32.23 on Tuesday. Stoke Therapeutics, Inc. has a 12-month low of $12.86 and a 12-month high of $40.22. The firm has a market capitalization of $2.08 billion, a PE ratio of -9.65 and a beta of 1.20. The firm has a 50-day moving average price of $30.49 and a 200 day moving average price of $32.10.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. On average, research analysts expect that Stoke Therapeutics, Inc. will post -3.5 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on STOK shares. Guggenheim reissued a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Canaccord Genuity Group reduced their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Get Our Latest Stock Analysis on Stoke Therapeutics

About Stoke Therapeutics

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.